查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1539344

感染疾病診斷市場:全球產業分析，規模，佔有率，成長，趨勢，預測，2024-2033年

Infectious Diseases Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
出版日期: | 出版商: Persistence Market Research | 英文 241 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

Persistence Market Research最近發布了一份關於全球傳染病診斷市場的深入研究報告，提供了對市場推動因素、趨勢、機會和課題等市場動態的詳細見解。本報告旨在提供對市場結構和未來前景的全面了解，特別是醫療保健和診斷領域的利害關係人。

主要洞察

  • 全球市場收入（2022 年）：351 億美元
  • 預計市場價值（2033 年）：551 億美元
  • 全球市場成長率（2022-2033 年複合年增長率）：4.2%

全球傳染病診斷市場 - 報告範圍：

新興市場包括用於識別傳染病的診斷測試套件和系統的開發、生產和分銷。該市場涵蓋多種疾病，包括呼吸道感染、性傳染感染（STI）以及其他需要及時準確診斷才能有效治療的傳染病。

推動市場成長的因素：

傳染病發生率增加

全球傳染病流行持續加劇，增加了對有效診斷解決方案的需求。呼吸道疾病和性傳染病的發生率尤其高，需要加強診斷檢測來管理和控制這些疾病。例如，根據世界銀行的數據，2020年將有3,770萬人感染愛滋病毒，其中一半是婦女和女孩。對此類感染的準確診斷和及時治療的需求預計將推動對傳染病診斷的需求。

越來越多地關注實證醫學 (EBM)

實證醫學 (EBM) 在醫療保健環境中變得越來越重要，因為它可以幫助臨床醫生實現更高品質的照護、提高病患滿意度並降低成本。 EBM不僅利用證據來制定治療方案，還鼓勵患者和臨床醫生之間的對話，讓患者參與決策。對實證診斷的重視正在推動對診斷試劑盒的需求，因為臨床醫生依靠準確的診斷結果來指導治療決策。

對快速診斷測試 (RDT) 的需求不斷增加

隨著越來越多的患者患有需要快速且準確診斷的傳染病，對快速診斷測試 (RDT) 的需求不斷增加。例如，世界衛生組織 (WHO) 報告稱，2010 年至 2020 年間，全球銷售了 31 億粒治療瘧疾的 RDT，其中 81% 銷往撒哈拉以南非洲國家。對可靠且低成本的診斷試劑盒的需求不斷增加，為市場成長創造了重大機會。

市場課題

診斷測試套件成本高

雖然傳染病診斷市場正在擴大，但可用診斷測試套件的高成本仍然是一個主要課題。需要具有高特異性和敏感性的經濟高效的檢測試劑盒來使診斷更容易，特別是在資源匱乏的環境中。目前診斷工具的高成本限制了其廣泛使用，特別是在發展中國家。

缺乏有效的診斷測試套件

許多傳染病的高效診斷檢測試劑盒供不應求。開發負擔得起且可靠的檢測試劑盒對於滿足高收入和低收入地區不斷增長的診斷需求至關重要。越來越多的公司正在專注於研發高精度和靈敏的診斷試劑盒，這有望在市場上創造新的商機。

成長機會：

聚焦傳染病預防

各國都將重點放在傳染病預防上，以減少醫療支出。例如，印度健康基金會與印度政府首席科學顧問辦公室合作，呼籲進行創新，以解決影響傳染病控制、治療和治癒的緊迫問題。隨著政府和醫療機構尋求加強其診斷能力，此類措施為傳染病診斷試劑盒供應商提供了重大的成長機會。

擴大研發

擴大旨在製造高精度和靈敏診斷試劑盒的研發預計將為從事傳染病診斷的公司創造新的業務前景。專注於技術創新和開發更有效的診斷解決方案預計將在未來幾年推動市場成長。

本報告涵蓋的主要問題

  • 推動全球傳染病診斷市場成長的關鍵因素有哪些？
  • 哪個消費族群正在推動傳染病診斷解決方案的採用？
  • 技術進步如何影響競爭格局？
  • 誰是全球傳染病診斷市場的主要參與者？
  • 全球傳染病診斷市場的新趨勢和未來前景是什麼？

目錄

第1章 摘要整理

第2章 市場概要

  • 市場範圍/分類
  • 市場定義/範圍/限制
  • 包含和排除

第3章 主要市場趨勢

  • 影響市場的主要趨勢
  • 產品革新/開發趨勢

第4章 重要成功要素

  • 生產引進分析
  • 法規情勢
  • 償付的形勢
  • 供應鏈分析
  • PESTEL分析
  • 波特分析

第5章 市場背景

  • 宏觀經濟要素
  • 預測要素- 相關性及影響
  • 市場動態

第6章 COVID-19危機分析

  • COVID-19及影響分析
  • 2024年的市場情勢

第7章 全球感染疾病診斷市場需求(金額)分析

  • 市場(金額)分析，2019～2023年
  • 市場(金額)預測，2024～2033年
    • 前一年同期比較成長趨勢分析
    • 絕對的商機

第8章 各產品:全球感染疾病診斷市場分析

  • 簡介/主要調查結果
  • 市場(金額)分析，2019～2023年
  • 市場(金額)預測，2024～2033年
  • 設備
    • 生物晶片
    • 微流體為基礎的POCT
    • DNA微陣列
    • 質譜分析
    • 即時聚合酵素鏈鎖反應(qPCR)
    • 螢光原位雜合反應(FISH)
    • 定序
    • 毛細管電泳法
    • 次世代定序
  • 套件和試劑
    • 套件
    • 一次抗體
    • 二次抗體
    • 基材
    • 緩衝
  • 消耗品
  • 各產品市場魅力分析

第9章 各檢驗類型:全球感染疾病診斷市場分析

  • 簡介/主要調查結果
  • 市場(金額)分析，2019～2023年
  • 市場(金額)分析與預測，2024～2033年
    • 篩檢檢驗
    • 診斷檢驗
  • 各檢驗類型的市場魅力分析

第10章 各應用領域:全球感染疾病診斷市場分析

  • 簡介/主要調查結果
  • 市場(金額)分析，2019～2023年
  • 市場(金額)分析與預測，2024～2033年
    • 院內感染
    • 性感染疾病(STD)
    • 敗血症
    • 腦膜炎
    • 呼吸系統感染疾病
    • HPV
    • 消化管感染疾病
    • 移植患者的感染疾病
    • B型肝炎和C型肝炎
    • 結核
    • 其他
  • 各應用領域的市場魅力分析

第11章 各終端用戶:全球感染疾病診斷市場分析

  • 簡介/主要調查結果
  • 市場規模(金額)分析，2019～2023年
  • 市場規模(金額)分析與預測，2024～2033年
    • 醫院
    • 診斷檢驗室
    • 診所
    • 學術調查機關
    • 其他

各終端用戶市場魅力分析

第12章 各地區:全球感染疾病診斷市場分析

  • 簡介
  • 市場規模(金額)分析，2019～2023年
  • 市場規模(金額)分析與預測，2024～2033年
    • 北美
    • 南美
    • 歐洲
    • 東亞
    • 南亞
    • 大洋洲
    • 中東及非洲(中東·非洲)
  • 各地區市場的魅力分析

第13章 北美的感染疾病診斷市場分析

第14章 南美的感染疾病診斷市場分析

第15章 歐洲的感染疾病診斷市場分析

第16章 東亞的感染疾病診斷市場分析

第17章 南亞的感染疾病診斷市場分析

第18章 大洋洲的感染疾病診斷市場

第19章 中東·非洲感染疾病診斷市場分析

第20章 市場結構分析

  • 各級企業市場分析
  • 主要企業的市場佔有率分析
  • 市場影響分析

第21章 競爭分析

  • 競爭儀表板
  • 競爭基準
  • 競爭詳細內容
    • Affymetrix, Inc.
    • Ambion, Inc.
    • Applera Corporation
    • Cenetron Diagnostics
    • Cepheid, Inc.
    • Chiron Corporation
    • Dharmacon, Inc.
    • Digene Corporation
    • Gen-Probe Incorporated
    • Innogenetics NV
    • Nanogen, Inc.
    • F. Hoffmann-La Roche Ltd
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Hologic, Inc.
    • QIAGEN
    • Myriad Genetics, Inc.
    • Thermo Fisher Scientific
    • Meridian Bioscience, Inc.

第22章 所使用的前提條件與縮寫

第23章 調查手法

簡介目錄
Product Code: PMRREP11413

Persistence Market Research has recently published an in-depth report on the global infectious diseases diagnostics market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, particularly for stakeholders in the healthcare and diagnostics sectors.

Key Insights:

  • Global Market Revenue (2022): US$ 35.1 Billion
  • Estimated Market Value (2033): US$ 55.1 Billion
  • Global Market Growth Rate (CAGR 2022-2033): 4.2%

Global Infectious Diseases Diagnostics Market - Report Scope:

The infectious diseases diagnostics market includes the development, production, and distribution of diagnostic test kits and systems used to identify infectious diseases. The market covers a wide range of diseases, including respiratory infections, sexually transmitted infections (STIs), and other contagious diseases that require timely and accurate diagnosis for effective treatment.

Market Growth Drivers:

Rising Incidence of Infectious Diseases

The global prevalence of infectious diseases continues to rise, driving demand for effective diagnostic solutions. Respiratory diseases and sexually transmitted infections are particularly on the rise, necessitating increased diagnostic testing to manage and control these diseases. For instance, according to World Bank data, 37.7 million people were living with HIV in 2020, with women and girls comprising half of this population. The need for accurate diagnosis and timely treatment of such infections is expected to boost the demand for infectious diseases diagnostics.

Rising Focus on Evidence-Based Medicine (EBM)

Evidence-based medicine (EBM) is gaining importance in the healthcare environment as it helps clinicians achieve higher quality care, improved patient satisfaction, and lower costs. EBM not only involves using evidence to develop treatment protocols but also encourages dialogue between patients and clinicians, allowing patients to participate in decision-making. The emphasis on evidence-based diagnosis is driving the demand for diagnostic kits, as clinicians rely on accurate diagnostic results to guide treatment decisions.

Increasing Demand for Rapid Diagnostic Tests (RDTs)

The demand for rapid diagnostic tests (RDTs) is growing as more patients suffer from infectious diseases that require quick and accurate diagnosis. For example, the World Health Organization (WHO) reported that 3.1 billion RDTs for malaria were sold worldwide between 2010 and 2020, with 81% of these sales going to sub-Saharan African nations. The need for reliable, low-cost diagnostic kits is increasing, presenting significant opportunities for market growth.

Market Challenges:

High Cost of Diagnostic Test Kits

While the market for infectious diseases diagnostics is expanding, the high cost of available diagnostic test kits remains a significant challenge. There is a need for cost-effective test kits with high specificity and sensitivity to make diagnostics more accessible, particularly in low-resource settings. The high cost of current diagnostic tools limits their widespread adoption, especially in developing countries.

Lack of Efficient Diagnostic Test Kits

There is a scarcity of efficient diagnostic test kits for many infectious diseases. The development of affordable and reliable test kits is essential to meet the growing demand for diagnostics in both high-income and low-income regions. Companies are increasingly focusing on research and development to create highly accurate and sensitive diagnostic kits, which is expected to open up new business opportunities in the market.

Opportunities for Growth:

Focus on Infectious Disease Prevention

Different nations are concentrating on preventing infectious diseases to reduce healthcare expenditures. For example, the India Health Fund, in collaboration with the Office of the Principal Scientific Adviser to the Government of India, is calling for innovations to address urgent issues affecting the control, treatment, and cure of infectious diseases. Such initiatives present strong growth opportunities for suppliers of diagnostic kits for infectious diseases, as governments and healthcare organizations seek to enhance their diagnostic capabilities.

Expansion of Research and Development Efforts

The expanding research and development efforts aimed at producing highly accurate and sensitive diagnostic kits are expected to create new business prospects for companies involved in infectious diseases diagnostics. The focus on innovation and the development of more effective diagnostic solutions will likely drive the market's growth in the coming years.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global infectious diseases diagnostics market?
  • Which consumer segments are leading the adoption of infectious diseases diagnostic solutions?
  • How are technological advancements influencing the competitive landscape?
  • Who are the key players in the global infectious diseases diagnostics market, and what strategies are they employing to maintain their market position?
  • What are the emerging trends and future prospects in the global infectious diseases diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global infectious diseases diagnostics market, such as Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, are focusing on product innovation, strategic collaborations, and expanding their market presence in emerging economies. These companies are investing heavily in research and development to create advanced diagnostic kits that offer enhanced accuracy and affordability. Collaborations with healthcare providers and governments are enhancing market credibility and driving the adoption of new technologies.

Key Companies Profiled:

  • Affymetrix, Inc.
  • Ambion, Inc.
  • Applera Corporation
  • Cenetron Diagnostics
  • Cepheid, Inc.
  • Chiron Corporation
  • Dharmacon, Inc.
  • Digene Corporation
  • Gen-Probe Incorporated
  • Innogenetics NV
  • Nanogen, Inc.
  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Hologic, Inc.,
  • QIAGEN
  • Myriad Genetics, Inc.,
  • Thermo Fisher Scientific
  • Meridian Bioscience, Inc.

Key Segments Covered in Infectious Diseases Diagnostics Industry Research

Product:

  • Instrument
  • Kits and reagents
  • consumables

Test Type:

  • Screening Test
  • Diagnostic Test

Application:

  • Hospital- Acquired Infections
  • Sexually Transmitted Disease (STD)
  • Sepsis
  • Meningitis
  • Respiratory Infections
  • HPV
  • Gastrointestinal Tract Infections
  • Infection in Transplant Patients
  • Hepatitis B and C
  • Tuberculosis
  • Others

End User:

  • Hospitals
  • Diagnostic Laboratories
  • Clinics
  • Academic and Research Institutes
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Production Adoption Analysis
  • 4.2. Regulatory Scenario
  • 4.3. Reimbursement Landscape
  • 4.4. Supply Chain Analysis
  • 4.5. PESTEL Analysis
  • 4.6. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Parent Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Development of Novel Products
    • 5.2.2. Regulatory Imposition
    • 5.2.3. Increasing Demand for Rapid Diagnostic Kits
    • 5.2.4. Increasing Production Launches
    • 5.2.5. Growing Government Investment
    • 5.2.6. Strategic Mergers and Acquisitions Among Local
    • 5.2.7. High Demand for PoC Testing
    • 5.2.8. Rising Awareness about Early Testing
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Product
    • 6.1.2. By Test Type
    • 6.1.3. By Application
    • 6.1.4. By End User
    • 6.1.5. By Region
  • 6.2. 2024 Market Scenario

7. Global Infectious Disease Diagnostic Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis, by Product, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Product, 2024-2033
  • 8.4. Instrument
    • 8.4.1. Biochips
    • 8.4.2. Microfluidics Based POCT
    • 8.4.3. DNA Microarrays
    • 8.4.4. Mass Spectrometry
    • 8.4.5. Real-time Polymerase Chain Reaction (qPCR)
    • 8.4.6. Fluorescence in situ Hybridization (FISH)
    • 8.4.7. Sequencing
    • 8.4.8. Capillary Electrophoresis
    • 8.4.9. Next Generation Sequencing
  • 8.5. Kits and reagents
    • 8.5.1. Kits
    • 8.5.2. Primary antibodies
    • 8.5.3. Secondary antibodies
    • 8.5.4. Substrates
    • 8.5.5. Buffers
  • 8.6. consumables
  • 8.7. Market Attractiveness Analysis, by Product

9. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Test Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Test Type, 2024-2033
    • 9.3.1. Screening Test
    • 9.3.2. Diagnostic Test
  • 9.4. Market Attractiveness Analysis, by Test Type

10. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Application

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Application, 2024-2033
    • 10.3.1. Hospital- Acquired Infections
    • 10.3.2. Sexually Transmitted Disease (STD)
    • 10.3.3. Sepsis
    • 10.3.4. Meningitis
    • 10.3.5. Respiratory Infections
    • 10.3.6. HPV
    • 10.3.7. Gastrointestinal Tract Infections
    • 10.3.8. Infection in Transplant Patients
    • 10.3.9. Hepatitis B and C
    • 10.3.10. Tuberculosis
    • 10.3.11. Others
  • 10.4. Market Attractiveness Analysis, by Application

11. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By End User

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by End User, 2024-2033
    • 11.3.1. Hospitals
    • 11.3.2. Diagnostic Laboratories
    • 11.3.3. Clinics
    • 11.3.4. Academic and Research Institutes
    • 11.3.5. Others

Market Attractiveness Analysis, by End User

12. Global Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Analysis, by Region, 2019-2023
  • 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis, by Region

13. North America Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Product
    • 13.3.3. By Test Type
    • 13.3.4. By Application
    • 13.3.5. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Product
    • 13.4.3. By Test Type
    • 13.4.4. By Application
    • 13.4.5. By End User
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Infectious Disease Diagnostic Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.1.2.1. By Product
        • 13.8.1.2.2. By Test Type
        • 13.8.1.2.3. By Application
        • 13.8.1.2.4. By End User
    • 13.8.2. Canada Infectious Disease Diagnostic Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.2.2.1. By Product
        • 13.8.2.2.2. By Test Type
        • 13.8.2.2.3. By Application
        • 13.8.2.2.4. By End User

14. Latin America Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Mexico
      • 14.3.1.2. Brazil
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Product
    • 14.3.3. By Test Type
    • 14.3.4. By Application
    • 14.3.5. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By Test Type
    • 14.4.4. By Application
    • 14.4.5. By End User
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Mexico Infectious Disease Diagnostic Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.1.2.1. By Product
        • 14.8.1.2.2. By Test Type
        • 14.8.1.2.3. By Application
        • 14.8.1.2.4. By End User
    • 14.8.2. Brazil Infectious Disease Diagnostic Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.2.2.1. By Product
        • 14.8.2.2.2. By Test Type
        • 14.8.2.2.3. By Application
        • 14.8.2.2.4. By End User
    • 14.8.3. Argentina Infectious Disease Diagnostic Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.3.2.1. By Product
        • 14.8.3.2.2. By Test Type
        • 14.8.3.2.3. By Application
        • 14.8.3.2.4. By End User

15. Europe Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Russia
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Product
    • 15.3.3. By Test Type
    • 15.3.4. By Application
    • 15.3.5. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Product
    • 15.4.3. By Test Type
    • 15.4.4. By Application
    • 15.4.5. By End User
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Infectious Disease Diagnostic Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.1.2.1. By Product
        • 15.8.1.2.2. By Test Type
        • 15.8.1.2.3. By Application
        • 15.8.1.2.4. By End User
    • 15.8.2. Italy Infectious Disease Diagnostic Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.2.2.1. By Product
        • 15.8.2.2.2. By Test Type
        • 15.8.2.2.3. By Application
        • 15.8.2.2.4. By End User
    • 15.8.3. France Infectious Disease Diagnostic Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.3.2.1. By Product
        • 15.8.3.2.2. By Test Type
        • 15.8.3.2.3. By Application
        • 15.8.3.2.4. By End User
    • 15.8.4. U.K. Infectious Disease Diagnostic Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.4.2.1. By Product
        • 15.8.4.2.2. By Test Type
        • 15.8.4.2.3. By Application
        • 15.8.4.2.4. By End User
    • 15.8.5. Spain Infectious Disease Diagnostic Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.5.2.1. By Product
        • 15.8.5.2.2. By Test Type
        • 15.8.5.2.3. By Application
        • 15.8.5.2.4. By End User
    • 15.8.6. BENELUX Infectious Disease Diagnostic Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.6.2.1. By Product
        • 15.8.6.2.2. By Test Type
        • 15.8.6.2.3. By Application
        • 15.8.6.2.4. By End User
    • 15.8.7. Russia Infectious Disease Diagnostic Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.7.2.1. By Product
        • 15.8.7.2.2. By Test Type
        • 15.8.7.2.3. By Application
        • 15.8.7.2.4. By End User

16. East Asia Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market End User (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Product
    • 16.3.3. By Test Type
    • 16.3.4. By Application
    • 16.3.5. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Product
    • 16.4.2. By Test Type
    • 16.4.3. By Application
    • 16.4.4. By End User
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Infectious Disease Diagnostic Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.1.2.1. By Product
        • 16.8.1.2.2. By Test Type
        • 16.8.1.2.3. By Application
        • 16.8.1.2.4. By End User
    • 16.8.2. Japan Infectious Disease Diagnostic Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.2.2.1. By Product
        • 16.8.2.2.2. By Test Type
        • 16.8.2.2.3. By Application
        • 16.8.2.2.4. By End User
    • 16.8.3. South Korea Infectious Disease Diagnostic Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.3.2.1. By Product
        • 16.8.3.2.2. By Test Type
        • 16.8.3.2.3. By Application
        • 16.8.3.2.4. By End User

17. South Asia Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Indonesia
      • 17.3.1.3. Malaysia
      • 17.3.1.4. Thailand
      • 17.3.1.5. Rest of South Asia
    • 17.3.2. By Product
    • 17.3.3. By Test Type
    • 17.3.4. By Application
    • 17.3.5. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By Test Type
    • 17.4.4. By Application
    • 17.4.5. By End User
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. India Infectious Disease Diagnostic Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.1.2.1. By Product
        • 17.8.1.2.2. By Test Type
        • 17.8.1.2.3. By Application
        • 17.8.1.2.4. By End User
    • 17.8.2. Indonesia Infectious Disease Diagnostic Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.2.2.1. By Product
        • 17.8.2.2.2. By Test Type
        • 17.8.2.2.3. By Application
        • 17.8.2.2.4. By End User
    • 17.8.3. Malaysia Infectious Disease Diagnostic Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.3.2.1. By Product
        • 17.8.3.2.2. By Test Type
        • 17.8.3.2.3. By Application
        • 17.8.3.2.4. By End User
    • 17.8.4. Thailand Infectious Disease Diagnostic Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.4.2.1. By Product
        • 17.8.4.2.2. By Test Type
        • 17.8.4.2.3. By Application
        • 17.8.4.2.4. By End User

18. Oceania Infectious Disease Diagnostic Market 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Product
    • 18.3.3. By Test Type
    • 18.3.4. By Application
    • 18.3.5. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Product
    • 18.4.3. By Test Type
    • 18.4.4. By Application
    • 18.4.5. By End User
  • 18.5. Key Market Participants - Intensity Mapping
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Infectious Disease Diagnostic Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.1.2.1. By Product
        • 18.8.1.2.2. By Test Type
        • 18.8.1.2.3. By Application
        • 18.8.1.2.4. By End User
    • 18.8.2. New Zealand Infectious Disease Diagnostic Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.2.2.1. By Product
        • 18.8.2.2.2. By Test Type
        • 18.8.2.2.3. By Application
        • 18.8.2.2.4. By End User

19. Middle East and Africa (MEA) Infectious Disease Diagnostic Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkiye
      • 19.3.1.3. South Africa
      • 19.3.1.4. North Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Product
    • 19.3.3. By Test Type
    • 19.3.4. By Application
    • 19.3.5. By End User
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Product
    • 19.4.2. By Test Type
    • 19.4.3. By Application
    • 19.4.4. By End User
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Infectious Disease Diagnostic Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.1.2.1. By Product
        • 19.8.1.2.2. By Test Type
        • 19.8.1.2.3. By Application
        • 19.8.1.2.4. By End User
    • 19.8.2. Turkiye Infectious Disease Diagnostic Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.2.2.1. By Product
        • 19.8.2.2.2. By Test Type
        • 19.8.2.2.3. By Application
        • 19.8.2.2.4. By End User
    • 19.8.3. South Africa Infectious Disease Diagnostic Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.3.2.1. By Product
        • 19.8.3.2.2. By Test Type
        • 19.8.3.2.3. By Application
        • 19.8.3.2.4. By End User
    • 19.8.4. North Africa Infectious Disease Diagnostic Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.4.2.1. By Product
        • 19.8.4.2.2. By Test Type
        • 19.8.4.2.3. By Application
        • 19.8.4.2.4. By End User

20. Market Structure Analysis

  • 20.1. Market Analysis, by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Affymetrix, Inc.
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Sales Footprint
      • 21.3.1.4. Key Financials
      • 21.3.1.5. SWOT Analysis
      • 21.3.1.6. Strategy Overview
        • 21.3.1.6.1. Marketing Strategy
        • 21.3.1.6.2. Product Strategy
        • 21.3.1.6.3. Channel Strategy
    • 21.3.2. Ambion, Inc.
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Sales Footprint
      • 21.3.2.4. Key Financials
      • 21.3.2.5. SWOT Analysis
      • 21.3.2.6. Strategy Overview
        • 21.3.2.6.1. Marketing Strategy
        • 21.3.2.6.2. Product Strategy
        • 21.3.2.6.3. Channel Strategy
    • 21.3.3. Applera Corporation
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Sales Footprint
      • 21.3.3.4. Key Financials
      • 21.3.3.5. SWOT Analysis
      • 21.3.3.6. Strategy Overview
        • 21.3.3.6.1. Marketing Strategy
        • 21.3.3.6.2. Product Strategy
        • 21.3.3.6.3. Channel Strategy
    • 21.3.4. Cenetron Diagnostics
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Sales Footprint
      • 21.3.4.4. Key Financials
      • 21.3.4.5. SWOT Analysis
      • 21.3.4.6. Strategy Overview
        • 21.3.4.6.1. Marketing Strategy
        • 21.3.4.6.2. Product Strategy
        • 21.3.4.6.3. Channel Strategy
    • 21.3.5. Cepheid, Inc.
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Sales Footprint
      • 21.3.5.4. Key Financials
      • 21.3.5.5. SWOT Analysis
      • 21.3.5.6. Strategy Overview
        • 21.3.5.6.1. Marketing Strategy
        • 21.3.5.6.2. Product Strategy
        • 21.3.5.6.3. Channel Strategy
    • 21.3.6. Chiron Corporation
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Sales Footprint
      • 21.3.6.4. Key Financials
      • 21.3.6.5. SWOT Analysis
      • 21.3.6.6. Strategy Overview
        • 21.3.6.6.1. Marketing Strategy
        • 21.3.6.6.2. Product Strategy
        • 21.3.6.6.3. Channel Strategy
    • 21.3.7. Dharmacon, Inc.
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Sales Footprint
      • 21.3.7.4. Key Financials
      • 21.3.7.5. SWOT Analysis
      • 21.3.7.6. Strategy Overview
        • 21.3.7.6.1. Marketing Strategy
        • 21.3.7.6.2. Product Strategy
        • 21.3.7.6.3. Channel Strategy
    • 21.3.8. Digene Corporation
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Sales Footprint
      • 21.3.8.4. Key Financials
      • 21.3.8.5. SWOT Analysis
      • 21.3.8.6. Strategy Overview
        • 21.3.8.6.1. Marketing Strategy
        • 21.3.8.6.2. Product Strategy
        • 21.3.8.6.3. Channel Strategy
    • 21.3.9. Gen-Probe Incorporated
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Sales Footprint
      • 21.3.9.4. Key Financials
      • 21.3.9.5. SWOT Analysis
      • 21.3.9.6. Strategy Overview
        • 21.3.9.6.1. Marketing Strategy
        • 21.3.9.6.2. Product Strategy
        • 21.3.9.6.3. Channel Strategy
    • 21.3.10. Innogenetics NV
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Sales Footprint
      • 21.3.10.4. Key Financials
      • 21.3.10.5. SWOT Analysis
      • 21.3.10.6. Strategy Overview
        • 21.3.10.6.1. Marketing Strategy
        • 21.3.10.6.2. Product Strategy
        • 21.3.10.6.3. Channel Strategy
    • 21.3.11. Nanogen, Inc.
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Sales Footprint
      • 21.3.11.4. Key Financials
      • 21.3.11.5. SWOT Analysis
      • 21.3.11.6. Strategy Overview
        • 21.3.11.6.1. Marketing Strategy
        • 21.3.11.6.2. Product Strategy
        • 21.3.11.6.3. Channel Strategy
    • 21.3.12. F. Hoffmann-La Roche Ltd
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Sales Footprint
      • 21.3.12.4. Key Financials
      • 21.3.12.5. SWOT Analysis
      • 21.3.12.6. Strategy Overview
        • 21.3.12.6.1. Marketing Strategy
        • 21.3.12.6.2. Product Strategy
        • 21.3.12.6.3. Channel Strategy
    • 21.3.13. Becton, Dickinson and Company
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Sales Footprint
      • 21.3.13.4. Key Financials
      • 21.3.13.5. SWOT Analysis
      • 21.3.13.6. Strategy Overview
        • 21.3.13.6.1. Marketing Strategy
        • 21.3.13.6.2. Product Strategy
        • 21.3.13.6.3. Channel Strategy
    • 21.3.14. bioMerieux SA
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Sales Footprint
      • 21.3.14.4. Key Financials
      • 21.3.14.5. SWOT Analysis
      • 21.3.14.6. Strategy Overview
        • 21.3.14.6.1. Marketing Strategy
        • 21.3.14.6.2. Product Strategy
        • 21.3.14.6.3. Channel Strategy
    • 21.3.15. Hologic, Inc.
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Sales Footprint
      • 21.3.15.4. Key Financials
      • 21.3.15.5. SWOT Analysis
      • 21.3.15.6. Strategy Overview
        • 21.3.15.6.1. Marketing Strategy
        • 21.3.15.6.2. Product Strategy
        • 21.3.15.6.3. Channel Strategy
    • 21.3.16. QIAGEN
      • 21.3.16.1. Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Sales Footprint
      • 21.3.16.4. Key Financials
      • 21.3.16.5. SWOT Analysis
      • 21.3.16.6. Strategy Overview
        • 21.3.16.6.1. Marketing Strategy
        • 21.3.16.6.2. Product Strategy
        • 21.3.16.6.3. Channel Strategy
    • 21.3.17. Myriad Genetics, Inc.
      • 21.3.17.1. Overview
      • 21.3.17.2. Product Portfolio
      • 21.3.17.3. Sales Footprint
      • 21.3.17.4. Key Financials
      • 21.3.17.5. SWOT Analysis
      • 21.3.17.6. Strategy Overview
        • 21.3.17.6.1. Marketing Strategy
        • 21.3.17.6.2. Product Strategy
        • 21.3.17.6.3. Channel Strategy
    • 21.3.18. Thermo Fisher Scientific
      • 21.3.18.1. Overview
      • 21.3.18.2. Product Portfolio
      • 21.3.18.3. Sales Footprint
      • 21.3.18.4. Key Financials
      • 21.3.18.5. SWOT Analysis
      • 21.3.18.6. Strategy Overview
        • 21.3.18.6.1. Marketing Strategy
        • 21.3.18.6.2. Product Strategy
        • 21.3.18.6.3. Channel Strategy
    • 21.3.19. Meridian Bioscience, Inc.
      • 21.3.19.1. Overview
      • 21.3.19.2. Product Portfolio
      • 21.3.19.3. Sales Footprint
      • 21.3.19.4. Key Financials
      • 21.3.19.5. SWOT Analysis
      • 21.3.19.6. Strategy Overview
        • 21.3.19.6.1. Marketing Strategy
        • 21.3.19.6.2. Product Strategy
        • 21.3.19.6.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology